前列腺癌中的血管生成抑制：当前应用与未来前景。
Angiogenesis inhibition in prostate cancer: current uses and future promises.
机构信息
Division of Hematology and Oncology, Department of Medicine, The George Washington University Medical Center, 2150 Pennsylvania Avenue Northwest, Washington, DC 20037, USA.
出版信息
J Oncol. 2010;2010:361836. doi: 10.1155/2010/361836. Epub 2010 Feb 11.
Abstract
Angiogenesis has been well recognized as a fundamental part of a multistep process in the evolution of cancer progression, invasion, and metastasis. Strategies for inhibiting angiogenesis have been one of the most robust fields of cancer investigation, focusing on the vascular endothelial growth factor (VEGF) family and its receptors. There are numerous regulatory drug approvals to date for the use of these agents in treating a variety of solid tumors. While therapeutic efficacy has been established, challenges remain with regards to overcoming resistance and assessing response to antiangiogenic therapies. Prostate cancer is the most common noncutaneous malignancy among American men and angiogenesis plays a role in disease progression. The use of antiangiogenesis agents in prostate cancer has been promising and is hereby explored.
摘要
血管生成已被充分认识为癌症进展、浸润和转移这一多步骤过程的基本组成部分。抑制血管生成的策略一直是癌症研究中最活跃的领域之一，重点是血管内皮生长因子（VEGF）家族及其受体。迄今为止，已有许多调节药物批准用于治疗各种实体瘤。虽然已经确定了治疗效果，但在克服耐药性和评估抗血管生成治疗反应方面仍存在挑战。前列腺癌是美国男性中最常见的非皮肤恶性肿瘤，血管生成在疾病进展中起作用。抗血管生成药物在前列腺癌中的应用具有广阔前景，在此进行探讨。
相似文献
1
Angiogenesis inhibition in prostate cancer: current uses and future promises.前列腺癌中的血管生成抑制：当前应用与未来前景。
J Oncol. 2010;2010:361836. doi: 10.1155/2010/361836. Epub 2010 Feb 11.
2
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.癌症治疗中针对血管生成：超越血管内皮生长因子
Oncologist. 2015 Jun;20(6):660-73. doi: 10.1634/theoncologist.2014-0465. Epub 2015 May 22.
3
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.血管内皮细胞生长因子（VEGF），一种新兴的癌症化疗靶点。
Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. doi: 10.2174/1568011033353452.
4
Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.抗血管生成治疗面临的挑战：低氧诱导因子和 MET 在抗血管内皮生长因子靶向治疗耐药中的重要作用。
J Cell Physiol. 2019 May;234(5):5655-5663. doi: 10.1002/jcp.27414. Epub 2018 Dec 4.
5
Angiogenesis inhibitors in the treatment of prostate cancer.血管生成抑制剂在前列腺癌治疗中的应用。
Expert Opin Pharmacother. 2010 Feb;11(2):233-47. doi: 10.1517/14656560903451716.
6
Antiangiogenic agents in cancer therapy.癌症治疗中的抗血管生成药物。
Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):17-25.
7
Angiogenesis and prostate cancer: important laboratory and clinical findings.血管生成与前列腺癌：重要的实验室及临床研究发现
Curr Oncol Rep. 2005 May;7(3):215-9. doi: 10.1007/s11912-005-0076-z.
8
Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.前列腺癌转移过程中血管内皮生长因子和信号素配体-受体家族的失调。
BMC Syst Biol. 2015 Sep 4;9:55. doi: 10.1186/s12918-015-0201-z.
9
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.组蛋白去乙酰化酶抑制剂NVP-LAQ824可抑制血管生成，与血管内皮生长因子受体酪氨酸激酶抑制剂PTK787/ZK222584联合使用时具有更强的抗肿瘤作用。
Cancer Res. 2004 Sep 15;64(18):6626-34. doi: 10.1158/0008-5472.CAN-04-0540.
10
Assessing the in vivo efficacy of biologic antiangiogenic therapies.评估生物抗血管生成疗法的体内疗效。
Cancer Chemother Pharmacol. 2013 Jan;71(1):1-12. doi: 10.1007/s00280-012-1978-8. Epub 2012 Oct 9.
引用本文的文献
1
Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets.前列腺癌中的血管生成与抗血管生成治疗：作用机制与分子靶点
Int J Mol Sci. 2021 Sep 14;22(18):9926. doi: 10.3390/ijms22189926.
2
Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening.前列腺癌中的离子通道分析：迈向细胞群体特异性筛选。
Rev Physiol Biochem Pharmacol. 2021;181:39-56. doi: 10.1007/112_2020_22.
3
Delivery of the gene encoding the tumor suppressor Sef into prostate tumors by therapeutic-ultrasound inhibits both tumor angiogenesis and growth.治疗超声将肿瘤抑制基因 Sef 递送入前列腺肿瘤，可抑制肿瘤血管生成和生长。
Sci Rep. 2017 Nov 8;7(1):15060. doi: 10.1038/s41598-017-12408-1.
4
Adrenergic nerves activate an angio-metabolic switch in prostate cancer.肾上腺素能神经激活前列腺癌中的血管代谢开关。
Science. 2017 Oct 20;358(6361):321-326. doi: 10.1126/science.aah5072.
5
CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.肿瘤基质中的CD47缺陷通过增强血管生成促进肿瘤进展。
Oncotarget. 2017 Apr 4;8(14):22406-22413. doi: 10.18632/oncotarget.9899.
6
Microvascular density and immunohistochemical expression of VEGF, VEGFR-1 and VEGFR-2 in benign prostatic hyperplasia, high-grade prostate intraepithelial neoplasia and prostate cancer.良性前列腺增生、高级别前列腺上皮内瘤变和前列腺癌中微血管密度以及血管内皮生长因子（VEGF）、血管内皮生长因子受体-1（VEGFR-1）和血管内皮生长因子受体-2（VEGFR-2）的免疫组化表达
Cent European J Urol. 2016;69(1):63-71. doi: 10.5173/ceju.2016.726. Epub 2016 Jan 25.
7
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.TRC105抗内皮糖蛋白（CD105）抗体用于转移性去势抵抗性前列腺癌的I期研究。
BJU Int. 2015 Oct;116(4):546-55. doi: 10.1111/bju.12986. Epub 2015 Jun 8.
8
Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.卵巢癌细胞系（OvCar-3）和前列腺癌细胞系（PC-3）中，响应骨桥蛋白-c剪接异构体过表达时转录谱的变化。
BMC Cancer. 2014 Jun 13;14:433. doi: 10.1186/1471-2407-14-433.
9
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.加拿大转移性去势抵抗性前列腺癌治疗中的药物成本。
BMC Health Serv Res. 2014 Jun 13;14:252. doi: 10.1186/1472-6963-14-252.
10
Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.凝血酶敏感蛋白-1在泌尿系统癌症中的作用：病理作用、临床意义及治疗前景
Int J Mol Sci. 2013 Jun 7;14(6):12249-72. doi: 10.3390/ijms140612249.
本文引用的文献
1
Reply to the letter "About sorafenib in castration-resistant prostate cancer" by G. Colloca, F. Checcaglini and A. Venturino.对G. 科洛卡、F. 切卡利尼和A. 文图里诺所写的《关于索拉非尼治疗去势抵抗性前列腺癌》信件的回复。
Ann Oncol. 2008 Oct;19(10):1813-1814. doi: 10.1093/annonc/mdn549. Epub 2019 Dec 3.
2
Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study.前瞻性研究前列腺肿瘤血管生成与癌症特异性死亡率在卫生保健人员随访研究中的作用。
J Clin Oncol. 2009 Nov 20;27(33):5627-33. doi: 10.1200/JCO.2008.20.8876. Epub 2009 Oct 26.
3
The role of vascular endothelial growth factor genetic variability in cancer.血管内皮生长因子基因变异性在癌症中的作用。
Clin Cancer Res. 2009 Sep 1;15(17):5297-302. doi: 10.1158/1078-0432.CCR-08-2576. Epub 2009 Aug 25.
4
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
5
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.来那度胺口服制剂用于难治性转移性癌症患者的I期研究。
J Clin Pharmacol. 2009 Jun;49(6):650-60. doi: 10.1177/0091270009335001.
6
Phase II study of sunitinib in men with advanced prostate cancer.舒尼替尼用于晚期前列腺癌男性患者的II期研究。
Ann Oncol. 2009 May;20(5):913-20. doi: 10.1093/annonc/mdp111.
7
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.阿柏西普（AVE0005）：一种通过血管内皮生长因子抑制肿瘤血管生成的替代策略。
Expert Opin Biol Ther. 2009 Feb;9(2):263-71. doi: 10.1517/14712590802666397.
8
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.一项使用索拉非尼治疗转移性去势抵抗性前列腺癌的II期试验的最终分析。
BJU Int. 2009 Jun;103(12):1636-40. doi: 10.1111/j.1464-410X.2008.08327.x. Epub 2009 Jan 9.
9
Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study.索拉非尼治疗去势抵抗性前列腺癌患者的安全性和疗效：一项 II 期研究。
Urol Oncol. 2010 Jan-Feb;28(1):21-7. doi: 10.1016/j.urolonc.2008.06.003. Epub 2008 Sep 12.
10
About sorafenib in castration-resistant prostate cancer.关于索拉非尼在去势抵抗性前列腺癌中的应用。
Ann Oncol. 2008 Oct;19(10):1812-3; author reply 1813-1814. doi: 10.1093/annonc/mdn546. Epub 2008 Aug 9.
Zotero 插件